A B S T R A C T Plasma low density lipoprotein (LDL) transport kinetics were determined from the disappearance of '251-LDL injected into age-and weightmatched groups of 13 normal subjects, 20 mild diabetics, and 8 moderately severe diabetic patients (fasting plasma glucose <150 and >150 mg/100 ml, respectively). In mild diabetics, LDL apo-lipoprotein-B (apo-B) synthetic rate (SR) was significantly greater than normal. The fractional catabolic rate (FCR), however, was also increased so that plasma LDL concentration remained normal. In moderately severe diabetics, LDL SR was normal but FCR was reduced resulting in increased plasma LDL cholesterol and apo-B concentrations. In normal subjects, moderate obesity was associated with increased LDL secretion. In diabetic subjects, however, changes in LDL turnover were of equal magnitude in obese and nonobese patients. In normolipemic and hyperlipemic mild diabetic subjects with equal degrees of glucose intolerance, both LDL apo-B SR and FCR were greater than normal. The magnitude of these increases, however, was lower in the hyperlipemic individuals. Stepwise regression analysis revealed that both LDL SR and FCR correlated positively and linearly with insulin response to glucose loading, but negatively and curvilinearly with fasting plasma glucose and glucose response. We plasma LDL levels. These changes cannot be attributed to the presence of obesity or hypertriglyceridemia, and may relate to varying degrees of insulin resistance and decreased insulin secretion affecting plasma very low density lipoprotein (VLDL) secretion, VLDL conversion to LDL, and LDL catabolism. Both increased LDL turnover in mild diabetes and delayed removal of LDL in moderately severe diabetes could increase cholesterol ester availability to peripheral tissues, and may result in an increased risk of atherosclerosis.
A B S T R A C T Plasma low density lipoprotein (LDL) transport kinetics were determined from the disappearance of '251-LDL injected into age-and weightmatched groups of 13 normal subjects, 20 mild diabetics, and 8 moderately severe diabetic patients (fasting plasma glucose <150 and >150 mg/100 ml, respectively). In mild diabetics, LDL apo-lipoprotein-B (apo-B) synthetic rate (SR) was significantly greater than normal. The fractional catabolic rate (FCR), however, was also increased so that plasma LDL concentration remained normal. In moderately severe diabetics, LDL SR was normal but FCR was reduced resulting in increased plasma LDL cholesterol and apo-B concentrations. In normal subjects, moderate obesity was associated with increased LDL secretion. In diabetic subjects, however, changes in LDL turnover were of equal magnitude in obese and nonobese patients. In normolipemic and hyperlipemic mild diabetic subjects with equal degrees of glucose intolerance, both LDL apo-B SR and FCR were greater than normal. The magnitude of these increases, however, was lower in the hyperlipemic individuals. Stepwise regression analysis revealed that both LDL SR and FCR correlated positively and linearly with insulin response to glucose loading, but negatively and curvilinearly with fasting plasma glucose and glucose response. We propose that in noninsulin-dependent diabetes, mild hyperglycemia is accompanied by increased LDL turnover, despite normal plasma LDL levels, whereas moderately severe hyperglycemia is associated with decreased LDL catabolism, resulting in increased
INTRODUCTION
In man, plasma low density lipoprotein (LDL)' plays a major role in the transport of cholesterol ester (CHE) to peripheral tissues. Abnormalities in the metabolic behavior of this lipoprotein could lead to accelerated delivery of CHE to vascular structures, resulting in an increased risk of atherosclerosis. As recently reviewed (1, 2), '90% of CHE formed is initially transferred to very low density lipoprotein (VLDL). During catabolism of VLDL, a major fraction of its apolipoprotein-B (apo-B) together with CHE becomes associated with LDL. The LDL particle can acquire additional CHE in the circulation (1) and under certain conditions LDL may be secreted directly into the plasma (3, 4) .
No detailed information is currently available concerning the effects of diabetes mellitus upon the in vivo metabolism of plasma LDL in man. There are several reasons, however, to suspect that the abnormal milieu in this disease might adversely affect the met-abolic behavior of LDL. First, the increased cholesterol synthesis (5) and cholesterol esterifying capacity (lecithin:cholesterol acyltransferase activity) (6) and the relative enrichment of LDL with triglycerides (7) suggest an abnormality in the formation of VLDL, its conversion to LDL, or both. Indeed, we have recently shown that enhanced VLDL apo-B secretion is a fundamental defect in diabetes and that in -some diabetic individuals, conversion of VLDL to LDL is greater than normal (8) . Second, the lack of insulin action in diabetes, whether due to insulin resistance, decreased insulin secretion, or both, might impair receptor-mediated uptake and catabolism of LDL, as it does in cultured cells in vitro (9, 10) . Third, the nonenzymatic glycosylation of LDL apo-B, if it occurs to a significant extent in vivo, could affect the catabolic rate and the metabolic fate of LDL (11). Finally, diabetes is frequently associated with obesity and hyperlipidemia and these disorders may independently affect plasma LDL transport.
The present study was therefore undertaken to examine the in vivo kinetics of plasma LDL transport in well-defined groups of noninsulin-dependent diabetic subjects, separating the effects of diabetes from those due to associated obesity and hyperlipidemia. The relationships of prevailing plasma insulin levels and severity of hyperglycemia to the disorder in LDL transport were also explored.
METHODS
Subjects. Kinetic Significantly different from nonobese subjects in the same group, P < 0.001.
I Significantly different from normals, P < 0.005. § Significantly different from normolipemic mild diabetics, P < 0.001.
roid, liver, and kidney function. Patients with morbid obesity, extreme lipemia, gross proteinuria, history of excessive alcohol consumption, or intake of drugs known to affect lipid or carbohydrate metabolism were excluded. The presence of either acute illness or severe diabetes (plasma glucose concentrations at 7 and 11 a.m. and at 4 and 10 p.m. >300 mg/ 100 ml) requiring immediate management were contraindications for participation in the study. The diagnosis of diabetes was based upon the criteria of the National Diabetes Data Group (12) . Diabetes was considered to be present when plasma glucose concentration in both the 2-h sample and in another sample exceeded 200 mg/100 ml. Diabetic subjects were separated according to their fasting plasma glucose (FPG) concentration into two main groups: mild diabetics (FPG <150 mg/100 ml) and moderately severe diabetics (FPG >150 mg/100 ml). As shown in Table I , the three groups (normal, mild diabetics, and moderately severe diabetics) were comparable in composition with respect to age, sex, body weight, and percentage of ideal body weight. Ideal body weight for the midpoint of the range for medium body frame was determined from the Metropolitan Life Insurance Company tables. Each group included both nonobese and moderately obese subjects (<120% and 120-150% of ideal body weight, respectively). The ratio of nonobese to obese individuals in each group was approximately equal.
Patients in the mild diabetic group included those with normal fasting plasma triglyceride levels of <150 mg/100 ml (within the 90th percentile of the similarly aged normal population) (13) , and those with fasting hypertriglyceridemia of >250 mg/100 ml (well above the 95th percentile for the normal population) (13) . The normolipemic and hyperlipemic subgroups were of similar age and weight and their fasting and postglucose challenge plasma concentrations were comparable. All of the moderately severe diabetic patients were hyperlipemic but their mean plasma lipid levels were not significantly different from those of the hyperlipemic mild diabetic subjects (Table I) (1:1, vol:vol). The glass fiber disk containing the delipidated TMU-insoluble precipitate (apo-B) was transferred to a counting vial for radioassay. Samples of the injected tracer were treated simultaneously and the total dose of injected material was checked by weighing the syringe contents. Radioactivity was corrected for physical decay using '"I standard counted simultaneously. After radioassay, the TMUinsoluble proteins of the lipoprotein fraction were determined using a modification of the method of Lowry et al. (19) . Sodium hydroxide (0.2 ml of 2 mol/liter solution) was added to the radioactivity counting vial and the mixture allowed to stand overnight at room temperature. To this mixture 2.0 ml of Na2CO3 (40 g/liter) was added, followed by 0.04 ml of an aqueous solution of CuS04 (10 g/liter) and NaK tartrate (20 g/liter). After 10 min at room temperature, 0.2 ml of H2SO4 (1.0 mol/liter) was added, followed by 0.2 ml Folin reagent (0.5 mol/liter). The sample was then centrifuged for 10,000 g min and the clear supernatant aspirated for colorimetry. For Calculation and interpretation of results. The curve peeling technique of Matthews (20) was used to derive the exponential functions best describing the radioactivity decay data. In most subjects, two exponentials were observed but in two normal subjects and three diabetic patients, a third exponential was also found. The mean percentage of the total LDL pool removed during this third decay phase, however, was <8% of the total removal rate. Data analysis, therefore, was performed using the two-compartment model of Matthews. From the slopes of the two exponentials, b, and b2, and their intercepts with zero time axis, cl and c2, the fractional catabolic rate (FCR) was calculated as follows:
The synthetic rate (SR) of plasma LDL was then calculated as:
The steady-state LDL pool was determined from mean plasma LDL concentration and the initial distribution space of labeled LDL. The latter was derived from the radioactive dose and plasma radioactivity 10 min after injection of the tracer.
In this calculation, it is assumed that the intravascular LDL pool equilibrates with, and is exchanging with, an extravascular pool and that catabolism of LDL protein is occurring at a site in close proximity to the intravascular compartment. It is also assumed that the metabolism of LDL during the experimental period is proceeding at a steady state and, hence, the absolute synthetic rate is equated to its rate of catabolism. In the present study, steady state was considered to be present when plasma LDL concentrations during the course of the investigation and the ratio of radioactivity in urine to that in plasma (U/P) varied by'<10%. Other methods. Plasma triglycerides and cholesterol were determined in venous blood obtained after an overnight fast. Plasma LDL (d 1.019-1.063) obtained quantitatively by ultracentrifugation was also subjected to cholesterol estimation. Analyses were performed using standard Lipid Research Clinic autoanalyzer II semiautomated techniques (21) . Oral glucose tolerance tests using 40 g of glucose/m2 body surface area were performed after an overnight fast. Plasma samples were collected between zero time and 120 min after oral glucose administration and analyzed for glucose (22) and immunoreactive insulin (23) . Glucose Relationship to obesity level. In obese normolipemic nondiabetic subjects, LDL apo-B synthesis was significantly higher than that of nonobese individuals (Table II) , LDL apo-B SR being positively correlated with the percentage of ideal body weight (r = 0.55, P <0.05). LDL apo-B FCR, however, was not significantly different between obese and nonobese individuals. Both plasma LDL apo-B and cholesterol concentrations were higher in the obese subjects but remained within the normal range.
Among normolipemic and hyperlipemic mild diabetic patients, the rate of LDL apo-B synthesis increased in both the nonobese and obese individuals to the same extent (Table II) . Furthermore, no significant differences were found between obese and nonobese subjects with respect to their LDL apo-B FCR or LDL apo-B and cholesterol concentrations. Similarly, no significant differences in LDL apo-B turnover measurements were found between obese and nonobese individuals with moderately severe diabetes.
Relationship to hyperlipidemia. Relationship to plasma insulin and glucose. Table  III shows that in mild diabetic patients with or without hyperlipemia, the mean fasting plasma insulin concentration was significantly higher than in normal subjects. Moderately severe diabetic subjects also tended to have increased fasting plasma insulin. This increase, however, did not attain statistical significance, a wide range of fasting plasma insulin (9 to 40 MU/ml) being observed in this group. During oral glucose challenge, normolipemic mild diabetic patients achieved a significantly higher plasma insulin response than normal subjects. Compared to normolipemic mild diabetics, patients with hyperlipemia and a similar degree of glucose intolerance had a lower insulin response that was not significantly different from the normal subjects. The insulin response of moderately severe diabetic patients, on the other hand, was significantly lower than normal. Fig. 2 shows that among all of the diabetic subjects studied, the rate of LDL apo-B synthesis was linearly correlated with the insulin response to oral glucose administration. With decreasing insulin response, LDL apo-B SR was proportionately reduced (r = 0.80, P < 0.001). As shown in Fig. 3 , decreases in plasma insulin response were also associated with declining LDL FCR (r = 0.89, P < 0.001). No significant correlations were observed between fasting plasma insulin levels and any of the LDL kinetic indices.
A negative curvilinear relationship was found between fasting plasma glucose concentration and both LDL apo-B SR (Fig. 4) and LDL apo-B FCR (Fig. 5) . Similar (Table II) .
Stepwise multiple regression analysis, however, revealed that in diabetic patients, plasma LDL apo-B SR and FCR were most strongly related to the insulin response (P < 0.0001 and < 0.0001, respectively), whereas their association with plasma glucose levels did not contribute a significant, independent effect. 
DISCUSSION
Elevated plasma levels of cholesterol and LDL cholesterol are among the factors predisposing to an increased incidence of coronary heart disease in diabetes (26, 27 (34) . In the present study, moderate obesity in normolipemic nondiabetic subjects was associated with increased LDL apo-B synthesis, this increase being proportionate to the level of obesity. The effects of diabetes upon plasma LDL transport kinetics, however, could not be accounted for by the presence of obesity since the changes in LDL turnover were equally manifest in nonobese and obese individuals. Furthermore, obesity did not exert an additive effect to that of diabetes.
Hyperlipidemia is another common feature of noninsulin-dependent diabetes, -40% of diabetic patients having increased plasma VLDL levels (35) . Endogenous hypertriglyceridemia is associated with enhanced production of cholesterol (36) , VLDL triglycerides (37, 38) , and apo-B (39). The increased LDL turnover in the mild diabetics, however, cannot be attributed to the presence of hypertriglyceridemia since (a) nondiabetic individuals with familial hypertriglyceridemia do not have increased LDL synthesis (4, 30), a major fraction of VLDL being removed from the plasma as remnant VLDL particles (40) ; (b) none of our patients had a history of familial lipoprotein disorder; and (c) the increase in LDL turnover in mild diabetics was present in normolipemic as well as hyperlipemic patients. Furthermore, the coexistence of hypertriglyceridemia with mild diabetes resulted in a decrease rather than an increase in LDL turnover; hypertriglyceridemic mild diabetic subjects had significantly lower LDL SR and FCR than normolipemic subjects with an equal degree of glucose intolerance, and hypertriglyceridemic moderately severe diabetics had still lower LDL turnover rates.
In normal subjects, LDL particles are thought to be derived solely from VLDL catabolism (4). In patients with familial hypercholesterolemia (4) and some hypertriglyceridemic individuals (41), however, a fraction of the LDL is secreted directly into the plasma without prior formation of VLDL. As shown in Fig.  6 , LDL apo-B synthetic rate in our diabetic patients correlated closely with the rate of LDL formation from VLDL reported previously in the same subjects (8) . The intercept of the line representing this correlation with the vertical axis was not significantly different from zero, indicating that in diabetic patients, as in normal subjects, LDL synthesis could be largely accounted for by its formation from VLDL. With currently available techniques, however, estimates of VLDL apo-B secretion and its conversion to LDL are approximations, and hence, formation of LDL from other sources cannot be entirely excluded.
The effects of diabetes on plasma LDL metabolism may result from complex interactions between varying degrees of insulin resistance, decreased insulin secretion, hyperglycemia, and increased FFA flux, which characterize the abnormal metabolic milieu in this syndrome (42) (43) (44) . These interactions could affect plasma LDL transport at three major sites: VLDL secretion, LDL formation from VLDL, and LDL catabolism.
Based upon the present findings and previous research, our overall interpretation of the effects of diabetes on these events is depicted in Fig. 7 . In noninsulin-dependent diabetic subjects with or without hypertriglyceridemia, VLDL secretion is increased (8, (44) (45) (46) . This increase may result from insulin resistance in peripheral tissues leading to an enhanced supply to the liver of glucose and FFA, both of which stimulate VLDL production. Insulin action in the liver, however, occurs at a much lower Km (halfmaximal effective insulin concentration (43) , and may remain unimpaired even in moderately severe diabetics so that insulin continues to support VLDL synthesis. Thus, despite the progressive decline in insulin response from normolipemic to hyperlipemic mild to hyperlipemic moderately severe diabetes, VLDL secretion rate is increased in all three groups as a result of the accompanying progressive increase in hepatic supply of glucose and FFA. This contrasts both with the situation in nondiabetic subjects, in whom the availability of these substrates is limited and the VLDL secretion rate is proportional to the degree of insulinemia (47, 48) , and with more severe forms of diabetes, in which extreme insulin deficiency may result in impaired VLDL secretion (46) . 107  122  179  96  150  172  118  100  198  104  146  206  116  88  174  139  129  188  140  150  179  132  106  186  128  96  184   105  116  100  96  106  112  126  142  134  129  136   425  340  330  305  276  298  420  380  460  396  286   269  198  218  202  182  198  238  216  220  196  189   118  486  222  98  294  216  104  384  209  108  316  234  139  278  211  138  494  214  136  362  206  142  310  198 Mild diabetic subjects 
